

MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Regd. Office: Upper Kesalton, Tallital, Nainital-263 001, Uttarakhand,

W: www.mescopharma.com E-mail: nsparameswaran@mescosteel.com, Tel: 9871862796

MPL/33/QTR-2/2020-2021

November 12, 2020

The Listing Department
BSE Limited
PhirozeJeejeebhoy Towers
Dalal Street
Mumbai-400001

Scrip ID: MESP HAR-B

Scrip Code: 500274

Sub: Un-Audited Financial Results for the Quarter ended 30th September, 2020

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Un-Audited Financial Results for the Quarter ended 30th September, 2020.

M/s. Sangram Paul & Co., Chartered Accountants, Statutory Auditors of the Company has issued the Limited Review Report


The Board meeting commenced at 02:00 pm and concluded at 03:00 pm

A Copy of the said results together with Limited Review Report is enclosed herewith. These results are also being made available on the website of the Company at www.mescopharma.com

This is for your information and records.

Thanking You,

Yours Faithfully,
For Mesco Pharmaceuticals Limited


N S Parameswaran
Company Secretary cum Compliance Officer

Sangram Paul & Co.

S.K. Paul. F.C.A
Chartered Accountant

Chartered Accountants
Plot No.-754/15, Jayadev Vihar, Bhubaneswar-751 013
Phone : 0674-2360863, Mob. : 9337116878

Limited Review Report on Unaudited Quarterly Financial Results of MESCO PHARMACEUTICALS LIMITED under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We have reviewed the accompanying statement of Standalone Unaudited financial results of **MESCO PHARMACEUTICALS LIMITED** for the quarter ended September 30, 2020 being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circular CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with Indian Accounting Standard ("IND-AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles general accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No: CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sangram Paul & Co.
Chartered Accountants
Firm Registration No. 308001E

S. K. Paul



S.K. Paul
Proprietor
M. No.: - 013015
UDIN:20013015AAAAAR2360
Date: 12th November, 2020

MESCO PHARMACEUTICALS LIMITED

Regd. Office : UPPER KESALTON TALLITAL NANITAL, UR 263001

Website: www.mescopharma.com, Tel.: 011-41587085, Email: nsparameswaran@mescosteel.com

STATEMENT OF STANDALONE UN AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2020

		(Figures in Rs.)				
		Part-I				
	Particulars	Quarter ended		Half Year Ended		Year ended
		30.09.2020 (Unaudited)	30.06.2020 (Unaudited)	30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
I	Revenue From Operations	-	-	-	-	-
II	Other Income	-	-	-	-	-
III	Total Income (I + II)	-	-	-	-	-
IV	EXPENSES					
	Cost of materials consumed	-	-	-	-	-
	Purchase of Stock-in Trade	-	-	-	-	-
	Changes in inventories of finished goods, Stock-in-Trade and work-in-	-	-	-	-	-
	Employee benefits expense	-	-	-	-	-
	Finance Cost	-	30	-	-	-
	Depreciation and amortisation expense	-	-	-	-	-
	Other Expenses	6,000	6,000	12,000	965,083	983,321
	Total Expenses (IV)	6,000	6,030	12,030	965,083	983,321
V	Profit/(loss) before exceptional items and tax (I-IV)	(6,000)	(6,030)	(12,030)	(965,083)	(983,321)
VI	Exceptional items	-	-	-	-	-
VII	Profit/(Loss) Before Tax (V-VI)	(6,000)	(6,030)	(12,030)	(965,083)	(983,321)
VIII	Tax Expense:					
	(1) Current Tax	-	-	-	-	-
IX	(2) Deferred Tax	-	-	-	-	-
	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	(6,000)	(6,030)	(12,030)	(965,083)	(983,321)
X	Profit/(Loss) from discontinued Operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax)(X+XI)	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	(6,000)	(6,030)	(12,030)	(965,083)	(983,321)
XIV	Other Comprehensive Income	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising	(6,000)	(6,030)	(12,030)	(965,083)	(983,321)
XVI	Earnings/(Loss) Per Equity Share (for continuing operation):					
	Basic and Diluted (face value of Rs. 10 each)	(0.00)	(0.00)	(0.00)	(0.05)	(0.05)
XVII	Earnings/(Loss) Per Equity Share (for discontinued operation):					
	Basic and Diluted (face value of Rs. 10 each)	-	-	-	-	-
XVIII	Earnings/(Loss) Per Equity Share (for discontinued and Continuing					
	Basic and Diluted (face value of Rs. 10 each)	(0.00)	(0.00)	(0.00)	(0.05)	(0.05)

Notes

1) The Company has adopted Indian Accounting Standards (IND AS) prescribed under the Companies Act, 2013 read with relevant rules thereunder, with effect from April 1, 2017 and accordingly these financial results have been prepared in accordance with the measurement and recognition principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with relevant rules made thereunder
2) The Statutory Auditors of the Company have carried out Limited Review of the above Results.
3) The above Un audited financial results for the quarter ended on September 30, 2020 have been reviewed by the Audit Committee and have been approved by the Board of Directors in its meeting held on 12th November, 2020
4) Previous year period figures have been rearranged and regrouped wherever necessary to make them comparable with current period figures.
5) There were no manufacturing activities in the Company during the period under consideration

Date : 12.11.2020
Place : New Delhi

For Mesco Pharmaceuticals Limited

Dhurv Singh

(Dhurv Singh)
Director & CEO
DIN: 02983286

MESCO PHARMACEUTICALS LIMITED

Regd. Office : UPPER KESALTON TALLITAL NANITAL, UR 263001

Website: www.mescopharma.com, Tel.: 011-41587085, Email: nsparameswaran@mescosteel.com

STATEMENT OF ASSETS AND LIABILITIES

(In Rs.)

	As at 30.09.2020 (Unaudited)	As at 31.03.2020 (audited)
ASSETS		
Non-current assets		
Property, plant and equipment	1,798,761.00	1,798,760.00
Capital work-in-progress	-	-
Investment Property	-	-
Non-current investments	1.00	1.00
Financial assets	-	-
Security deposit	-	-
Other financial assets	-	-
Other Non Current Assets	-	-
Current assets		
Inventories	-	-
Financial assets :	-	-
Trade receivables	-	-
Cash and cash equivalents	392,593.13	394,623
Loans	-	-
Other financial assets	-	-
Prepayments	-	-
	2,191,355.13	2,193,384
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share capital	197,381,000.00	197,381,000.00
(b) Other Equity		
Capital Reserve	-	-
Securities Premium	-	-
Treasury Shares	-	-
Retained Earnings	(307,525,375.66)	(307,513,346.16)
Reserve representing unrealised gains/losses	-	-
General Reserve	-	-
Other reserve	-	-
Total Equity	(110,144,375.66)	(110,132,346.16)
Non-current liabilities		
Financial liabilities:		
Borrowings	112,179,155.17	112,179,155.17
Trade Payables	-	-
Other Financial Liability	-	-
Deferred tax liabilities (net)	-	-
Other Non-Current liabilities	-	-
Current liabilities		
Short-term borrowings	-	-
Financial liabilities:		
Trade payables	156,576.00	146,575.00
Other Financial Liability	-	-
Other payables	-	-
Provisions	-	-
	2,191,355.51	2,193,384.01

FOR AND ON BEHALF OF THE BOARD

For Mesco Pharmaceuticals Limited

Dhruv Singh

Dhruv Singh
Director & CEO
DIN: 02983286

PLACE : NEW DELHI

DATED : 12.11.2020

Mesco Pharmaceuticals Limited Unaudited Cash Flow Statement for the period ended September 30, 2020 (Figures in Rs.)			
	Particulars	For the period ended 30th Sept, 2020	For the year ended 31st March, 2020
A.	<u>Cash Flow from Operating Activities</u>		
	Net Profit (Loss) before Tax & extra ordinary Item	(12,030)	(983,321)
	Adjustments for:		
	Impairment Loss		284,999
	Amortisation and Write off	-	-
	Operating profit before working capital changes	(12,030)	(698,322)
	Working Capital changes:		
	Trade receivables	-	-
	Short term loans and advances	-	-
	Short Term Provisions	-	(7,688)
	Trade payable	10,001	(81,725)
	Other current assets		-
	Cash generated from operations	(2,029)	(787,735)
	Direct Taxes Paid	-	-
	Net Cash from operating activities	(2,029)	(787,735)
B.	<u>Cash Flow from Investing Activities</u>		
	Change in Non-current investments	-	-
	Loans & Advances	-	-
	Interest on deposits	-	-
	Net Cash from investing activities	-	-
C.	<u>Cash Flow from Financing Activities</u>		
	Proceeds from issue of Share Capital	-	-
	Payment to Borrowings	-	-
	Proceeds from Loans and advances	-	786,440
	Net cash from financing activities	-	786,440
	Net change in cash & cash equivalent (A+B+C)	(2,029)	(1,295)
	Cash & Cash equivalents opening balance	394,622	395,917
	Cash & Cash Equivalents at the End of the Year	392,593	394,622

FOR AND ON BEHALF OF THE BOARD
For Mesco Pharmaceuticals Limited

Dhruv Singh

Date: 12.11.2020
Place: New Delhi

Dhruv Singh
Director & CEO
DIN: 02983286